Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label,
dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive,
castration-resistant, metastatic prostate cancer that has progressed after prior taxane
therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.